We serve Chemical Name:1-Oxa-8-azaspiro[4.5]decane hydrochloride CAS:3970-79-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![1-Oxa-8-azaspiro[4.5]decane hydrochloride](https://a.dearchem.com/CAS2/3970-79-4.png)
Chemical Name:1-Oxa-8-azaspiro[4.5]decane hydrochloride
CAS.NO:3970-79-4
Synonyms:1-oxa-8-azaspiro[4.5]decane,hydrochloride;1-Oxa-8-azaspiro[4.5]decane hydrochloride (1:1);1-Oxa-8-azaspiro[4.5]decane, hydrochloride (1:1);1-Oxa-8-azaspiro[4.5]decanhydrochlorid(1:1)
Molecular Formula:C8H16ClNO
Molecular Weight:177.672
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:267.4ºC at 760mmHg
Density:N/A
Index of Refraction:
PSA:21.26000
Exact Mass:177.092041
LogP:2.04980
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-oxa-8-azaspiro[4.5]decane,hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Oxa-8-azaspiro[4.5]decanhydrochlorid(1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Oxa-8-azaspiro[4.5]decane, hydrochloride (1:1) Use and application,1-Oxa-8-azaspiro[4.5]decanhydrochlorid(1:1) technical grade,usp/ep/jp grade.
Related News: Lonza’s Nansha site is fully integrated within the company’s global manufacturing network. Scientists and engineers based in Nansha focus on API development and manufacturing for customers around the globe. (+/-)-16-epiaspidofractine manufacturers As currently constituted, Vanamali employs roughly 140 works in Hyderabad, Telangana, that specialize in API starting materials and contract research, according to its website. Wavelength said the Indian firm currently sports enough capacity for research- to commercial-scale production of its drug intermediates. N-Dodecyl-N-methyl-1,2,3,4-tetrahydro-isochinolinium suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. N1-[(2R,3R)-7-chloro-5-[2-(dimethylamino)ethyl]-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N2-[(3,5-difluoro-phenyl)acetyl]-L-alaninamide vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. N1-[(2R,3R)-7-chloro-5-[2-(dimethylamino)ethyl]-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N2-[(3,5-difluoro-phenyl)acetyl]-L-alaninamide vendor & factory.
